Baidu
map

张宇辉教授:2016 ESC和AHA/AHA/HFSA心力衰竭新指南解读(二)慢性心力衰竭

2016-06-03 MedSci MedSci原创

2016年5月28日,由中国医师协会心力衰竭专业委员会、国家心血管病中心、北京力生心血管健康基金会联合主办的“心力衰竭国际学院”2016年第一期会议在北京顺利召开。会上,中国医学科学院阜外医院张宇辉教授对最新发布的《2016年ESC急性与慢性心力衰竭诊断与治疗指南》以及《2016年ACC/AHA/HFSA心力衰竭指南药物治疗部分更新》进行了详细的解读,并结合《中国心力衰竭诊断和治疗指南2014

2016年5月28日,由中国医师协会心力衰竭专业委员会、国家心血管病中心、北京力生心血管健康基金会联合主办的“心力衰竭国际学院”2016年第一期会议在北京顺利召开。会上,中国医学科学院阜外医院张宇辉教授对最新发布的《2016年ESC急性与慢性心力衰竭诊断与治疗指南》以及《2016年ACC/AHA/HFSA心力衰竭指南药物治疗部分更新》进行了详细的解读,并结合《中国心力衰竭诊断和治疗指南2014》进行了比较分析。

 
张宇辉教授

张宇辉教授介绍,《2016年ESC急性与慢性心力衰竭诊断与治疗指南》提出了很多新内容和新理念。与2012ESC心衰指南相比,在慢性心衰部分, 新指南的主要变化包括:

(1)提出了一个新的术语——HFmrEF(HF with midrange HF),即LVEF范围40%-49%的心力衰竭。将HFmrEF作为一个独立的组别有助于促进相关的研究,包括基本特征、病理生理以及治疗。

(2)对HFrEF、HFmrEF和HFpEF的诊断标准做了明确的推荐。

(3)基于心衰概率评估提出了新的非急性心衰诊断流程。

(4)推荐建议旨在预防或延缓明显的心衰,在出现症状前预防患者死亡。

(5)对sacubitril/缬沙坦的适应证做了推荐,该药是第一个ARNI类药物。

(6)修改了CRT的适应证。

一、心衰的诊断和分类

2016ESC心衰指南根据左心室射血分数(LVEF)将心衰分为HFrEF、HFmrEF和HFpEF,并对诊断标准做了明确的推荐。其中HFmrEF(HF with midrange HF),即LVEF范围40%-49%的心力衰竭。

表1 心衰的分类(2016ESC心衰指南)
 

备注:①LAE =左心房扩大;②LVH =左心室肥厚;③钠尿肽水平升高: BNP>35 pg/ml和/或NT-proBNP>125 pg/mL

张宇辉教授分析,这一理念在《2014中国心力衰竭诊断和治疗指南》和2013 ACC/AHA心衰管理指南中也有类似的表述,而且中国指南的分类更加细化。中国指南对心衰的分类如下:LVEF在41%~49%被称为临界HF-PEF,其人群特征、治疗及预后均与HF-REF类似,这提示将LVEF>50%作为临床诊断标准可能更好。此外,有的患者既往出现过LVEF下降至≤40%,其临床结局与LVEF持续性保留的患者可能也不同。

二、慢性心衰的诊断和治疗

(一)慢性心衰的诊断

2016ESC心衰指南提出了慢性心衰的诊断流程(如下图)。2012ESC心衰指南强调按照生物标志物和超声心动图进行诊断;而2016ESC心衰指南强调了临床症状、NT-proBNP以及超声心动图在心衰诊断中的作用。新指南流程图中,对于疑诊心衰的患者首先要根据临床病史和临床症状体征、体格检查和心电图进行评估。

 
图1 慢性心衰诊断流程

新指南中的NT-proBNP≥125pg/ml、BNP≥35pg/ml沿用了2012ESC心衰指南的标准。事实上,这一标准也并不是公认的。 《2014中国心力衰竭诊断和治疗指南》建议根据年龄、体重和肾功能对急性和慢性心衰的BNP和NT-proBNP的临界值进行调整;合并房颤也有相应的界定。对于慢性心衰患者, BNP和NT-proBNP的检测更多地用于排除心衰。此外,中国指南还提到了心肌损伤标志物等其他指标。

知识链接:
《2014中国心力衰竭诊断和治疗指南》关于标志物的推荐:
(1)BNP和NT-proBNP测定(I,A)可用于因呼吸困难而疑为心衰患者的诊断和鉴别诊断,BNP<35pg/ml、NT-proBNP<125 pg/ml时不支持慢性心衰诊断;也可用来评估慢性心衰的严重程度和预后(I,A);
(2)心肌损伤:肌钙蛋白可用于诊断原发病如急性心肌梗死,亦可以对心衰患者进一步的危险分层(I,A);
(3)其他生物学标志物:其他如纤维化、炎症、氧化应激、神经激素紊乱及心肌和基质重塑的标记物已经广泛应用于评价心衰的预后,如反应心肌纤维化的可溶性ST2(IIa,B)及半乳糖凝集素-3(IIb,B)等指标在慢性心衰的危险分层中可能提供额外信息。

(二)预防或延缓临床型心衰发生或死亡的治疗建议
 
1. 治疗高血压,以预防或延缓心衰发生并延长生命;

2. 无论是否伴有左室收缩功能异常,冠心病或具有冠心病高危因素者应接受他汀治疗,以预防或延缓心衰发生并延长生命;

3. 吸烟或酗酒者,应督促患者戒烟限酒,以预防或延缓心衰发生;

4. 应考虑治疗其他与心衰有关的危险因素(如肥胖与糖代谢异常),以预防或延缓心衰发生;

5. 应为2型糖尿病患者考虑应用恩格列净治疗,以预防或延缓心衰发生并延长生命;

6. 推荐无症状性左室功能异常与心肌梗死病史的患者应用ACEI治疗,以预防或延缓心衰发生并延长生命;

7. 建议不伴心肌梗死病史的无症状性左室功能异常的患者应用ACEI治疗,以预防或延缓心衰发生并延长生命;

8. 即便不存在左室收缩功能异常,稳定性冠心病患者均应考虑予以ACEI治疗,以预防或延缓心衰发生并延长生命;

9. 推荐无症状性左室收缩功能异常并伴心肌梗死病史的患者应用β受体阻滞剂治疗;

10. 推荐以下患者接受ICD治疗,以预防猝死并延长生命:1)急性心肌梗死至少40天后、缺血相关性无症状性左室收缩功能异常(LVEF≤30%)的患者;2)经过最佳药物治疗后的无症状性非缺血性扩张型心肌病(LVEF≤30%)的患者。

(三)HFrEF治疗

1.治疗流程
 
图2 HFrEF治疗流程

HFrEF治疗流程非常全面,涵盖了药物治疗和非药物治疗;并且用不同颜色标注了推荐级别,绿色为一级推荐,黄色为IIa级推荐。存在充血症状和体征的患者,建议使用利尿剂;经过最佳药物治疗LVEF仍≤35%或有症状性VT/VF病史的患者,推荐植入ICD。对于症状性HFrEF患者,首先给予ACEI和β受体阻滞剂,并强调上调到基于证据的最大耐受剂量。若无症状说明液体潴留不严重,可适当考虑减少利尿剂的剂量;若仍有症状且LVEF≤35%,可加用醛固酮受体拮抗剂(MRA)。若仍有症状且LVEF≤35%,分为以下三种情况:①若能够耐受ACEI或ARB,可替换为ARNI;②窦性心律、QRS间期≥130msc,可考虑CRT;③窦性心律、心率≥70bmp,可加用伊伐布雷定。对于难治性心衰患者,可考虑地高辛/肼苯哒嗪+硝酸异山梨醇酯/LVAD,或心脏移植;经上述治疗症状改善者,可减少利尿剂剂量。与2012年ESC指南相比,新指南主要增加了ARNI并调整了CRT推荐。

2.具体药物治疗推荐

(1)IA类推荐药物包括ACEI、β受体阻滞剂和MRA,旨在以降低心衰住院和死亡风险——对于症状性HFrEF患者,应在β受体阻滞剂基础上应用ACEI以降低患者因心衰住院与死亡风险;病情稳定的症状性HFrEF患者,应在ACEI治疗基础上应用β受体阻滞剂以降低患者因心衰住院与死亡风险;经过ACEI与β受体阻滞剂治疗后仍存在临床症状的HFrEF患者,推荐加用MRA。

(2)对于存在充血体征和/或症状的患者,推荐使用利尿剂以改善症状和运动能力(I,B)、降低心衰住院风险(IIa,B)。

(3)经过ACEI、β受体阻滞剂与MRA最佳治疗后仍有症状的HFrEF患者,推荐应用沙库巴曲/缬沙坦替代ACEI以进一步降低因心衰住院和死亡风险(I,B)。

(4)经过目标剂量或最大耐受量的β受体阻滞剂、ACEI(或ARB)和MRA充分治疗后仍有症状、LVEF≤35%且窦性心率≥70次/分的患者,应考虑使用伊伐布雷定降低心衰住院与心血管死亡风险(IIa,B);对于不能耐受β受体阻滞剂或存在该药禁忌证、有症状且LVEF≤35%且窦性心率≥70次/分患者应考虑接受伊伐布雷定治疗,此类患者应继续接受ACEI(或ARB)与MRA治疗(IIa,C);

(5)为减少因心衰住院和心血管死亡风险,不能耐受ACEI治疗的症状性心衰患者应接受ARB治疗,需同时接受β受体阻滞剂与MRA治疗(I,B);不能耐受MRA的患者,经过β受体阻滞剂治疗后仍存在症状,可考虑应用ARB治疗,以降低因心衰住院与死亡风险(IIb,C)。

(6)经过ACEI(或ARB)、β受体阻滞剂与MRA充分治疗后仍有症状且为窦性心律的心衰患者,可考虑应用地高辛治疗以降低住院风险(IIb,B)。

在欧美新指南中,ARNI均为I类推荐、B级证据,但推荐顺序和理念有一定差别。美国指南具体推荐如下表:

表3 2016AHA心衰指南药物治疗推荐
 

沙库巴曲 /缬沙坦(LCZ696)应用指征:(1)症状性心衰,LVEF≤40%;(2)BNP≥150pg/ml或NT-proBNP≥600pg/ml,或近12月内因心衰住院、BNP≥100pg/ml或NT-proBNP≥400 pg/ml;(3)能够耐受依那普利10mg bid。

沙库巴曲 /缬沙坦(LCZ696)应用说明:(1)其获得推荐是基于PARADIGM试验证据;(2)LCZ696用于伴有症状的射血分数减低的适宜慢性心衰患者(NYHA Ⅱ/Ⅲ),血压正常而且耐受ACEI或ARB合理剂量(Ⅰ,B-R);(3)目前缺如ARB和ARNI头对头比较研究,但新指南推荐,对于不适宜应用ACEI或ARNI的心衰患者,均可应用ARB。 

沙库巴曲 /缬沙坦(LCZ696)应用注意事项:(1)ARNI不应与ACEI合用,也不建议在ACEI最后一剂36小时之内使用(Ⅲ,B-R);(2)有血管性水肿病史的患者不应使用ARNI(Ⅲ,C-EO);(3)ARNI使用中应注意避免低血压;(4)目前ARNI有三种已核定的剂量,之一还未经PARADIGM试验检验; (5)推荐剂量49/51mg bid,目标剂量97/103mg bid。

表4 2016ESC心衰指南药物治疗剂量推荐
 

3.器械治疗推荐

表5 ICD和CRT治疗推荐(2016ESC心衰指南)
  

(四)HFpEF治疗

1.药物治疗推荐

在HFpEF药物治疗方面目前还缺乏强有力的证据。部分患者可根据危险因素及合并症选用ACEI(或ARB)、β受体阻滞剂及利尿剂等。

2.合并症推荐

合并房颤、快速心室率:可予胺碘酮,决奈达隆不能用于心衰患者;已经应用了β受体阻滞剂但不能控制心室率者,可加用地高辛。目前心衰合并房颤患者的靶心率尚无定论,目前2016 ESC指南推荐60-120 bmp。

合并缺铁性贫血:可考虑静脉补铁,可改善症状,但不能改善预后。

合并糖尿病:噻唑烷二酮类(格列酮类)药物会加重心衰、增加心衰住院风险,不推荐用于心衰患者。将恩格列净推荐用于2型糖尿病患者心衰的一级预防。

合并中枢性睡眠呼吸暂停:不推荐自适应伺服通气。

合并关节炎:不推荐NSAID和COX-2抑制剂。

3. 慢性有症状性HFrEF不推荐药物:
对于大部分慢性心衰患者,目前无证据支持使用他汀作为起始治疗药物有获益
除了房颤患者,无证据证明口服抗凝药较安慰剂和阿司匹林有明显获益
对于不伴CAD的HF患者,抗血小板治疗无明显获益,反而可能有胃肠道出血风险
不推荐肾素抑制剂作为ACEI或ARB的替代治疗

2016 ESC 心力衰竭新指南慢性心力衰竭部分总结:

(1)推荐应用新的流程来诊断非急性状态下的心衰,这种新流程主要基于疾病的临床可能性(信息采集自病史、体格检查和静息心电图)、循环利钠肽和经胸超声心动图的评估。

(2)推荐在疑诊或已确诊的心衰患者中进行经胸超声心动图,评估心肌的结构和功能,同时检测左室射血分数(LVEF)。指南将心衰分成三种类型:射血分数下降的心衰(HFrEF,LVEF<40%)、射血分数中间值的心衰(HFmrEF,LVEF 40%~49%)、射血分数保留的心衰(HFpEF,LVEF≥50%)。

(3)推荐治疗高血压,在冠心病或冠心病高危人群中应用他汀,在无症状的左室功能不全患者中应用ACEI,在无症状的左室功能不全和既往有心梗史的患者中使用β受体阻滞剂,以预防或延缓心衰的发生,延长寿命。

(4)推荐有症状的HFrEF患者终生应用改善预后的药物治疗,包括联合ACEI(如不能耐受ACEI则选用ARB)、β受体阻滞剂和MRA。如果患者接受上述治疗后仍持续有症状,推荐将ACEI替换为脑啡肽酶抑制剂沙库巴曲 /缬沙坦(LCZ696)。在有充血症状和体征的心衰患者中,推荐使用利尿剂以改善症状和运动耐量。

(5)对发生过血流动力学不稳定的室性心律失常幸存者,或至少给予最优化药物治疗3个月以上仍有症状且LVEF≤35%的心衰患者,推荐植入ICD,以降低猝死风险和全因死亡率。不推荐在心梗后40天内植入ICD,因为此时机不改善预后。

(6)对至少给予最优化药物治疗3个月以上仍有症状且LVEF≤35%、窦性心律、QRS波群宽度≥130 ms且呈左束支传导阻滞形态的心衰患者,推荐CRT以改善症状并降低死亡率。QRS波群宽度<130 ms是植入CRT的禁忌证。

(7)推荐在多学科护理和管理体系中协作收治心衰患者,以降低心衰的住院率和死亡率。

参考文献:

1. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the specia. Eur J Heart Fail. 2016 May 20.
2. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task. Circulation. 2016 May 22.
3. 中国心力衰竭诊断和治疗指南2014.中华心血管病杂志,2014,42(2):98-122

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1923338, encodeId=b05f19233384a, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Aug 10 07:25:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89206, encodeId=ee028920666, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f71734425, createdName=WEIXIN68842e27, createdTime=Fri Jun 10 13:21:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88671, encodeId=ae56886e1e9, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:20:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88545, encodeId=c7488854569, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:54:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251773, encodeId=ef3d1251e731a, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267306, encodeId=f2d5126e30633, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551751, encodeId=6a0a1551e51a7, content=<a href='/topic/show?id=305156401eb' target=_blank style='color:#2F92EE;'>#指南解读#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56401, encryptionId=305156401eb, topicName=指南解读)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb0214221999, createdName=shuangle, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1923338, encodeId=b05f19233384a, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Aug 10 07:25:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89206, encodeId=ee028920666, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f71734425, createdName=WEIXIN68842e27, createdTime=Fri Jun 10 13:21:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88671, encodeId=ae56886e1e9, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:20:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88545, encodeId=c7488854569, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:54:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251773, encodeId=ef3d1251e731a, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267306, encodeId=f2d5126e30633, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551751, encodeId=6a0a1551e51a7, content=<a href='/topic/show?id=305156401eb' target=_blank style='color:#2F92EE;'>#指南解读#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56401, encryptionId=305156401eb, topicName=指南解读)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb0214221999, createdName=shuangle, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-10 WEIXIN68842e27

    拜读

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1923338, encodeId=b05f19233384a, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Aug 10 07:25:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89206, encodeId=ee028920666, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f71734425, createdName=WEIXIN68842e27, createdTime=Fri Jun 10 13:21:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88671, encodeId=ae56886e1e9, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:20:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88545, encodeId=c7488854569, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:54:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251773, encodeId=ef3d1251e731a, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267306, encodeId=f2d5126e30633, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551751, encodeId=6a0a1551e51a7, content=<a href='/topic/show?id=305156401eb' target=_blank style='color:#2F92EE;'>#指南解读#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56401, encryptionId=305156401eb, topicName=指南解读)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb0214221999, createdName=shuangle, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-05 沉心多思

    不错的文章,多学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1923338, encodeId=b05f19233384a, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Aug 10 07:25:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89206, encodeId=ee028920666, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f71734425, createdName=WEIXIN68842e27, createdTime=Fri Jun 10 13:21:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88671, encodeId=ae56886e1e9, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:20:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88545, encodeId=c7488854569, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:54:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251773, encodeId=ef3d1251e731a, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267306, encodeId=f2d5126e30633, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551751, encodeId=6a0a1551e51a7, content=<a href='/topic/show?id=305156401eb' target=_blank style='color:#2F92EE;'>#指南解读#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56401, encryptionId=305156401eb, topicName=指南解读)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb0214221999, createdName=shuangle, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-05 沉心多思

    不错的文章,多学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1923338, encodeId=b05f19233384a, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Aug 10 07:25:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89206, encodeId=ee028920666, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f71734425, createdName=WEIXIN68842e27, createdTime=Fri Jun 10 13:21:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88671, encodeId=ae56886e1e9, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:20:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88545, encodeId=c7488854569, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:54:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251773, encodeId=ef3d1251e731a, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267306, encodeId=f2d5126e30633, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551751, encodeId=6a0a1551e51a7, content=<a href='/topic/show?id=305156401eb' target=_blank style='color:#2F92EE;'>#指南解读#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56401, encryptionId=305156401eb, topicName=指南解读)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb0214221999, createdName=shuangle, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1923338, encodeId=b05f19233384a, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Aug 10 07:25:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89206, encodeId=ee028920666, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f71734425, createdName=WEIXIN68842e27, createdTime=Fri Jun 10 13:21:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88671, encodeId=ae56886e1e9, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:20:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88545, encodeId=c7488854569, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:54:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251773, encodeId=ef3d1251e731a, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267306, encodeId=f2d5126e30633, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551751, encodeId=6a0a1551e51a7, content=<a href='/topic/show?id=305156401eb' target=_blank style='color:#2F92EE;'>#指南解读#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56401, encryptionId=305156401eb, topicName=指南解读)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb0214221999, createdName=shuangle, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-05 zhaohui6731
  7. [GetPortalCommentsPageByObjectIdResponse(id=1923338, encodeId=b05f19233384a, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Aug 10 07:25:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89206, encodeId=ee028920666, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f71734425, createdName=WEIXIN68842e27, createdTime=Fri Jun 10 13:21:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88671, encodeId=ae56886e1e9, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:20:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88545, encodeId=c7488854569, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:54:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251773, encodeId=ef3d1251e731a, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267306, encodeId=f2d5126e30633, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551751, encodeId=6a0a1551e51a7, content=<a href='/topic/show?id=305156401eb' target=_blank style='color:#2F92EE;'>#指南解读#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56401, encryptionId=305156401eb, topicName=指南解读)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb0214221999, createdName=shuangle, createdTime=Sun Jun 05 04:25:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]

相关资讯

PLoS One:伴有外周动脉疾病的心衰患者,卒中和死亡率较高

背景:伴有不同血管疾病的心脏衰竭患者,卒中和死亡风险研究较少。研究者进行了一项观察性研究,以评估不伴有房颤的心脏衰竭,存在外周动脉疾病(PAD)或心肌梗死(MI)患者,卒中和死亡的风险。方法:从丹麦全国登记记录中识别2000-2012年,诊断为无房颤的心衰患者。经过1年的随访,比较存在PAD,MI史或血管疾病史患者缺血性卒中和全因死亡的HR。结果:包括39357个心脏衰竭患者。与无血管疾病的心衰患

JACC:心脏指数降低不是心衰患者肾功能不全的主要驱动因素

人们普遍认为,心脏指数(CI)降低是心脏衰竭(HF)患者肾功能不全的一个显著贡献因子。然而,最近的数据却质疑了这一看法。这项研究旨在确定接受肺动脉导管(PAC)的HF患者的CI和肾功能之间的关系。ESCAPE(充血性心力衰竭和肺动脉导管有效性评估研究)试验包含了随机或注册部分的接受PAC的患者(n=575)。研究人员评估了多个亚组中CI和肾功能之间的关联,并评估非线性,阈值和纵向关系。在CI和估计

Psychosom Med:抑郁症可能影响心衰患者的远期生存率

已往研究证实抑郁可以用以预测心衰患者的全因死亡率,但是尚不清楚心衰患者的抑郁是否会影响远期生存率。近期发表于《身心医学》(Psychosomatic Medicine)的文章探讨了心衰患者抑郁对长期生存率的影响。该研究为前瞻性队列研究,入组了自1994年1月至1999年7月某城区医学研究中心662例心衰住院患者。研究者通过结构式访谈评估患者住院期间的抑郁状况,且在患者出院后一年内每季度进行规律评估

治疗心衰,你需要了解这些指标!

心力衰竭是一种复杂的临床征候群,是各种心脏病的终末期阶段,其预后较差,5年存活率与恶性肿瘤相似,而且较易反复发作,给患者及其家属带来严重的经济及思想负担。对于心衰的治疗急性期主要是以利尿、减轻心脏负荷为主,慢性期以改善心衰患者预后为最终目的。那么问题来了,我们怎么去评估患者心衰严重程度以及治疗效果?回答这个问题,我们需要了解下面这些指标:一、BNP(B型尿钠肽)先说指南:2014年中国心衰指南推荐

急性心衰,该如何处理?

近日,《中国心血管病报告2015》出炉,报告指出,目前心力衰竭患者平均年龄为(66±15)岁。什么情况是心衰来袭?临床上以急性左心衰最为常见,是一种严重的急危重症。当患者出现急性左心衰时,主要表现为突发的严重呼吸困难,呼吸频率加快、强迫坐位、烦躁、大汗,咳粉红色泡沫痰等。极重的患者可因脑缺血而致神志模糊。发病开始可有一过性血压升高,病情如不缓解,血压可持续下降直至休克。急性左心衰应与急性呼吸困难、

BMJ:β受体阻滞剂治疗射血分数减少的心衰患者,不受年龄和性别的影响

该研究的目的是通过汇集来自安慰剂对照随机试验中个体患者的数据来确定在射血分数减少(HFrEF)的心脏衰竭广泛年龄段的女性和男性患者中,β受体阻滞剂的疗效和耐受性。原始出处:Dipak Kotecha,Luis Manzano,Henry Krum,et al.Effect of age and sex on efficacy and tolerability of β blockers in pa

Baidu
map
Baidu
map
Baidu
map